ERR2598170
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 4
- umap1_2d
- -2.312318298
- umap2_2d
- -1.135096999
- umap1_3d
- -4.143603744
- umap2_3d
- 3.503773154
- umap3_3d
- -1.462302022
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.670
- MYC_TARGETS_V2+0.640
- MYC_TARGETS_V1+0.630
- G2M_CHECKPOINT+0.600
- UNFOLDED_PROTEIN_RESPONSE+0.430
- ANGIOGENESIS+0.420
- MTORC1_SIGNALING+0.410
- WNT_BETA_CATENIN_SIGNALING+0.380
- TGF_BETA_SIGNALING+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.290
- OXIDATIVE_PHOSPHORYLATION-0.220
- INTERFERON_GAMMA_RESPONSE-0.200
- TNFA_SIGNALING_VIA_NFKB-0.190
- COMPLEMENT-0.170
- KRAS_SIGNALING_UP-0.160
- HEDGEHOG_SIGNALING-0.140
- BILE_ACID_METABOLISM-0.130
- INFLAMMATORY_RESPONSE-0.120
- PEROXISOME-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598184 | fetal | fetal | 0.959 |
| 2 | ERR2598166 | fetal | fetal | 0.959 |
| 3 | ERR2598180 | fetal | fetal | 0.944 |
| 4 | ERR2598171 | fetal | fetal | 0.942 |
| 5 | ERR2598165 | fetal | fetal | 0.930 |
| 6 | ERR2598181 | fetal | fetal | 0.921 |
| 7 | ERR2598164 | fetal | fetal | 0.908 |
| 8 | ERR2598197 | fetal | fetal | 0.895 |
| 9 | ERR2598169 | fetal | fetal | 0.883 |
| 10 | ERR2598207 | fetal | fetal | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.670 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.640 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.430 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |